KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Assets for 16 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 22.38% to $2.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 billion through Dec 2025, up 22.38% year-over-year, with the annual reading at $2.5 billion for FY2025, 22.38% up from the prior year.
  • Assets for Q4 2025 was $2.5 billion at Halozyme Therapeutics, up from $2.2 billion in the prior quarter.
  • The five-year high for Assets was $2.5 billion in Q4 2025, with the low at $966.6 million in Q1 2021.
  • Average Assets over 5 years is $1.8 billion, with a median of $1.8 billion recorded in 2022.
  • The sharpest move saw Assets surged 126.21% in 2021, then decreased 5.88% in 2023.
  • Over 5 years, Assets stood at $1.1 billion in 2021, then skyrocketed by 66.74% to $1.8 billion in 2022, then dropped by 5.88% to $1.7 billion in 2023, then increased by 19.05% to $2.1 billion in 2024, then grew by 22.38% to $2.5 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $2.5 billion, $2.2 billion, and $2.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.